NICE recommends Takeda’s Ninlaro triplet regimen
20th January 2023 Uncategorised 0Therapy involves patients living with relapsed or refractory multiple myeloma More: NICE recommends Takeda’s Ninlaro triplet regimen Source: News
read more
Therapy involves patients living with relapsed or refractory multiple myeloma More: NICE recommends Takeda’s Ninlaro triplet regimen Source: News
read moreThe NICE recommendation followed data from clinical trials and real-world evidence More: NICE recommends PTC Therapeutics’ Translarna reimbursement Source: News
read moreSeagen’s targeted cancer med Tukysa picks up accelerated FDA nod in colorectal cancer esagonowsky Thu, 01/19/2023 – 15:39 More: Seagen's targeted cancer med Tukysa picks up accelerated FDA nod in colorectal cancer Source: fierce
read moreAlnylam, PTC Therapeutics rare disease drugs win backing from England’s NICE zbecker Thu, 01/19/2023 – 11:53 More: Alnylam, PTC Therapeutics rare disease drugs win backing from England's NICE Source: fierce
read moreIs the first NASH drug approval nearing? Intercept stages comeback as FDA sets decision date aliu Thu, 01/19/2023 – 11:06 More: Is the first NASH drug approval nearing? Intercept stages comeback as FDA sets decision date Source: fierce
read moreAmarin, in spat with activist investor, says Sarissa has ‘no plan and no new ideas’ kdunleavy Thu, 01/19/2023 – 10:11 More: Amarin, in spat with activist investor, says Sarissa has 'no plan and no new ideas' Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals